Jade Biosciences (JBIO) investor relations material

Pipeline overview and strategic focus

• Developing three advanced biologic assets for autoimmune diseases, all licensed from Paragon, with a focus on high-affinity, long half-life antibodies.

• Lead program JADE101 (anti-APRIL) targets IgAN, aiming for deep IgA reduction and convenient Q12-week dosing; phase II data expected in 2027, phase III to start 1H 2027.

• JADE201 (anti-BAFF receptor) in phase I for rheumatoid arthritis, with broad potential in B-cell mediated diseases; phase I data expected in 2027.

• JADE301 (anti-interferon beta) for dermatomyositis, with first-in-human dosing planned this year and data in 2027; designed for subcutaneous dosing.

• Programs supported by strong financials and a high-quality team.

IgAN clinical landscape and differentiation

• Recent phase III data from first-gen anti-APRIL/BAFF agents show eGFR stabilization, setting a new standard for IgAN therapy.

• JADE101 aims to replicate disease-modifying benefits and differentiate through convenience (infrequent sub-Q dosing) and deeper, faster IgA reduction.

• Guidelines emphasize strict proteinuria targets; JADE101's induction strategy seeks to achieve earlier and greater proteinuria reduction.

• Phase I data show 70% IgA reduction at induction dose, exceeding first-gen agents and maintained for 12 weeks post-dose.

• Phase II study ongoing with 30 patients, focusing on biomarker replication and proteinuria outcomes; robust data expected next year.

Regulatory and trial design updates

• FDA and NKF support for shorter, one-year eGFR endpoint trials in IgAN, reducing need for large, long placebo-controlled studies.

• Phase III for JADE101 will use a 12-month placebo-controlled design with proteinuria and eGFR as key endpoints, aiming for 400-450 patients.

• Accelerated timelines planned, with phase III initiation in 1H 2027, not contingent on phase II data completion.